Discover Biotech Webinar Pharma FDA & EMA ONCOLife Contact

ONCOLife

New Protein Modification Linked to IDH-Mutant Cancers Opens Therapeutic Possibilities

ONCOLife

Magnetic Nanoparticle-Guided Hyperthermia Opens a New Path for Advanced Solid Tumors

FDA & EMA

FDA Approves Nivolumab-AVD as First Immunotherapy Combination for Hodgkin Lymphoma

ONCOLife

Reengineering CAR-T Cells to Last Longer in the Fight Against Cancer and HIV

ONCOLife

Targeted Bladder Cancer Therapy Erda-iDRS Achieves 89% Response Rate and PDC

ONCOLife

Romiplostim Prevents Chemotherapy Side Effects and Preserves Treatment Intensity

ONCOLife

Vitamin B2’s Hidden Role in Cancer Survival May Open a New Therapeutic Target

ONCOLife Issues

Featured Articles

FDA Approves Agilent’s PD-L1 Test to Guide KEYTRUDA Use in Esophageal and GEJ Carcinoma

28 March 2026

Agilent has received FDA approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to identify patients with esophageal or gastroesophageal junction carcinoma eligible for pembrolizumab. The assay detects tumors with PD-L1 CPS ≥1...

Trending Articles

FDA Approves T-DXd Plus Pertuzumab as a First-Line Standard in HER2+ Breast Cancer

Less Toxic, More Effective: RW Evidence Supports Reduced Immunotherapy Dose in Melanoma

Clinical Trials

14 December 2025

Teclistamab plus Daratumumab Achieves an 83% Risk Reduction in R/R Multiple Myeloma

Clinical Trials

10 December 2025

FDA Approves AKEEGA for BRCA2+ Prostate Cancer as the First Precision Therapy

FDA & EMA

12 December 2025

GSK’s ADC Risvutatug Rezetecan Earns FDA Orphan Drug Status for Small Cell Lung Cancer

FDA & EMA

10 December 2025

Ribociclib Maintains Long-Term Disease Control in HR+ HER2 Metastatic Breast Cancer

Preoperative Radiation May Improve Immune Response in HR+ HER2- Breast Cancer

Clinical Trials

11 December 2025

Tucatinib Combination Cuts Progression Risk by 36% in HER2+ Metastatic Breast Cancer

Clinical Trials

10 December 2025

Giredestrant Cuts Risk of Invasive Recurrence by 30% in Early ER+ Breast Cancer

Clinical Trials

10 December 2025

CAR T Anito cel Delivers Deep, Durable Responses in R&R Multiple Myeloma

ONCOLife

9 December 2025

Lunsumio Combo Deliver High Response Rates in Follicular and Large B-Cell Lymphomas

Lung Organoids Offer a Revolutionary Path to Transform Drug Testing and Cancer Therapies

Biotech

2 December 2025

Nanotherapy Reprograms Glioblastoma Immunity Through Nose-to-Brain Delivery

ONCOLife

2 December 2025

Enozertinib Shows Strong Systemic and CNS Activity in EGFR Exon 20+ NSC Lung Cancer

Clinical Trials

6 December 2025

Colibactin’s Molecular Blueprint Exposes How a Gut Microbial Toxin Triggers Colorectal Cancer

ONCOLife

6 December 2025